title: In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.
abstract: Serum concentrations of Interleukin-6 (IL-6) were determined in renal cell carcinoma patients treated with low-dose subcutaneous human recombinant interleukin-2 (rIL-2). In all patients, administration of rIL-2 resulted in a significant increase in IL-6 serum levels to peak values within 4 to 6 hours as measured by enzyme-linked immunosorbent assays (ELISA). Repetitive administration of rIL-2 induced significantly lower IL-6 serum peaks when compared to the initial administration of rIL-2. Cumulative IL-6 release, as expressed by the area under the concentration curve (AUC), appeared to be independent of rIL-2 dose distribution (10 million IU rIL-2/m2 versus 20 million IU rIL-2/m2), and IL-6 serum peaks showed no direct dose dependency. Prior rIL-2 immunotherapy had no measurable effect on rIL-2 induced IL-6 release, while steroids resulted in a significant suppression of secondary IL-6 did not correlate with response to rIL-2 therapy or survival of rIL-2 treated renal cell carcinoma patients.
authors.affiliation: Division of Hematology and Oncology, Medizinische Hochschule Hannover, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Meffert
authors.forename: E L
authors.initials: EL
authors.lastname: Hanninen
authors.forename: T
authors.initials: T
authors.lastname: Menzel
authors.forename: A
authors.initials: A
authors.lastname: Schomburg
authors.forename: S
authors.initials: S
authors.lastname: Duensing
authors.forename: I
authors.initials: I
authors.lastname: Dallmann
authors.forename: J
authors.initials: J
authors.lastname: Grosse
authors.forename: S
authors.initials: S
authors.lastname: Vocke
authors.forename: J
authors.initials: J
authors.lastname: Buer
authors.forename: M
authors.initials: M
authors.lastname: Deckert
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000628:therapy*; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism*; D007680:Kidney Neoplasms / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007370:Interferon Type I; D007376:Interleukin-2; D015850:Interleukin-6; D011994:Recombinant Proteins; D003907:Dexamethasone